Literature DB >> 29391338

Expansion of a Myeloma-associated Lesion from Orbita to the Cerebrum.

Sinan Demircioğlu1, Demet Aydoğdu2, Özcan Çeneli1.   

Abstract

Entities:  

Keywords:  Multiple myeloma; Orbita Cerebrum.

Mesh:

Substances:

Year:  2018        PMID: 29391338      PMCID: PMC5843789          DOI: 10.4274/tjh.2017.0283

Source DB:  PubMed          Journal:  Turk J Haematol        ISSN: 1300-7777            Impact factor:   1.831


× No keyword cloud information.

To the Editor,

Involvement of the central nervous system due to multiple myeloma (MM) is a very exceptional presentation with an estimated rate of 1% of all cases [1], showing a poor survival duration of 1-2 months [2,3,4]. This involvement may present in three different patterns: 1) solitary plasmacytoma, 2) multiple plasmacytomas, and 3) cerebrospinal fluid involvement with plasma cells [5]. A 64-year-old female diagnosed with MM IgG kappa for 1 year was admitted with swelling and pain in the right eye. Physical examination was remarkable for proptosis. Laboratory evaluation revealed normocytic anemia, hypercalcemia, and M-protein peak in serum protein electrophoresis. Brain magnetic resonance imaging showed a retro-orbital mass of 5x6 cm in diameter extending to the right temporal region and cerebral parenchyma (Figure 1), leading to widespread edema (Figure 2). We did not evaluate the cerebrospinal fluid because it was an intracranial mass. The patient was diagnosed with recurrent MM and treated with VCD (bortezomib, cyclophosphamide, and dexamethasone). After four cycles of chemotherapy, significant clinical improvement including the regression of proptosis along with a decrease of radiological involvement was observed (Figure 3).
Figure 1

Cranial axial contrast magnetic resonance image before treatment: in the lateral aspect of the right orbit there is a mass lesion that expands and destroys the zygomatic bone and temporal lobe (red arrow). The mass lengthened in the cerebral parenchyma by invading the dura in the temporal region.

Figure 2

There is widespread edema (T2 axial images) around the joint due to cerebral parenchymal involvement.

Figure 3

Significant regression is seen in the lesion after treatment (red arrow).

  5 in total

1.  Emergence of central nervous system myeloma in the era of novel agents.

Authors:  Shane A Gangatharan; Dennis A Carney; H Miles Prince; Max M Wolf; E Henry Januszewicz; David S Ritchie; Simon J Harrison
Journal:  Hematol Oncol       Date:  2011-12-05       Impact factor: 5.271

2.  Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients.

Authors:  Alessandro Gozzetti; Alfonso Cerase; Flavia Lotti; Davide Rossi; Antonio Palumbo; Maria Teresa Petrucci; Francesca Patriarca; Chiara Nozzoli; Michele Cavo; Massimo Offidani; Michele Floridia; Salvatore Berretta; Roberto Vallone; Pellegrino Musto; Francesco Lauria; Elena Marchini; Alberto Fabbri; Stefania Oliva; Elena Zamagni; Fabiana Gentillini Sapienza; Stelvio Ballanti; Giuseppe Mele; Monica Galli; Maria Teresa Pirrotta; Francesco Di Raimondo
Journal:  Cancer       Date:  2011-08-25       Impact factor: 6.860

Review 3.  Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations.

Authors:  Athanasios B-T Fassas; Firas Muwalla; Tanya Berryman; Riad Benramdane; Lija Joseph; Elias Anaissie; Rajesh Sethi; Raman Desikan; David Siegel; Ashraf Badros; Amir Toor; Maurizio Zangari; Christopher Morris; Edgardo Angtuaco; Sajini Mathew; Carla Wilson; Aubrey Hough; Sami Harik; Bart Barlogie; Guido Tricot
Journal:  Br J Haematol       Date:  2002-04       Impact factor: 6.998

Review 4.  Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature.

Authors:  S L Petersen; A Wagner; P Gimsing
Journal:  Am J Hematol       Date:  1999-12       Impact factor: 10.047

Review 5.  Central nervous system myelomatosis: review of the literature.

Authors:  Laurens Nieuwenhuizen; Douwe H Biesma
Journal:  Eur J Haematol       Date:  2007-10-23       Impact factor: 2.997

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.